Teresa Soler-Monsó

RANKL inhibition spatially rewires the microenvironment of luminal breast cancer

Mario Rodriguez-del-Collado, Andrea Vethencourt, Alexandra Barranco, Jaime Martínez de Villarreal et autres

ABSTRACT Hormone receptor-positive, HER2-negative breast cancers are often poorly infiltrated by immune cells and derive limited benefit from current immunotherapy strategies. Here, using paired tumour samples from the randomised window-of-opportunity D-BIOMARK trial ( NCT03691311 ), we investigated the immunomodulatory effects of denosumab …

es, us (code pays fourni par la source)

Tumor-Infiltrating Lymphocytes as Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: Added Value of Morphological Characterization Beyond Quantification

Juan Azcarate, Anna Petit, Teresa Soler-Monsó, Eugenia Quiros et autres

Background/Objectives: Tumor-infiltrating lymphocytes (TILs) are recognized predictors of response to neoadjuvant chemotherapy (NACT) and prognosis in breast cancer, particularly in triple-negative (TN) and HER2-positive subtypes. However, the additional predictive value of morphological features of the inflammatory infiltrate beyond TIL quantification is not …

es (code pays fourni par la source)

Segmenting Invasive and In Situ Carcinoma in Breast WSIs with a Pretrained Histopathology Transformer

Lauren Jimenez-Martin, Felip Vilardell, Ana Petit, Eduard Dorca et autres

es (code pays fourni par la source)

Abstract P1-02-17: Rediscovering Denosumab: Immunomodulation of the Tumor Microenvironment in Early-Stage Breast Cancer through RANK Pathway Inhibition

Andrea Vethencourt, Eva María Trinidad, Eduard Dorca, Teresa Soler-Monsó et autres

Abstract Background: The RANK signaling pathway has emerged as a potential therapeutic target in breast cancer (BC). Preclinical and clinical data support that RANK inhibitors enhance the anti-tumor immune response. Recently, we have presented the primary outcomes of our window-of-opportunity clinical trial …

Breast Cancer Patient’s Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II–III Disease

Catalina Falo, Juan Azcarate, Sergi Fernández-González, Xavier Pérez et autres

Introduction: Neoadjuvant chemotherapy in breast cancer offers the possibility to facilitate breast and axillary surgery; it is a test of chemosensibility in vivo with significant prognostic value and may be used to tailor adjuvant treatment according to the response. Material and Methods: …

es (code pays fourni par la source)

Abstract PS16-04: Denosumab as an enhancer of the immune infiltrate in hormone receptor-positive early breast cancer. Subgroup analysis from the D-Biomark window-of-opportunity clinical trial (NCT03691311)

Andrea Vethencourt, Eva María Trinidad, Eduard Dorca, Anna Petit et autres

Abstract Background: The receptor activator of nuclear factor κB (RANK) signaling pathway has emerged as a therapeutic target in breast cancer (BC). Recent studies indicate that inhibition of the RANK pathway induces tumor cell differentiation and may enhance the anti-tumor immune response. …

es (code pays fourni par la source)

Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact

Amparo García‐Tejedor, Catalina Falo, Sergi Fernández-González, María Laplana et autres

es (code pays fourni par la source)

Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma

Agostina Stradella, Pablo Gargallo, Mónica Cejuela Solís, Anna Petit et autres

es (code pays fourni par la source)

Digital quantification of KI-67 in breast cancer

M. Sanchez, Teresa Soler-Monsó, Anna Petit, Juan Azcarate et autres

es (code pays fourni par la source)